Kelley RK, Gane E, Assenat E, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva , Lahn M, Faivre S, Benhadji KA, Giannelli G, Siebler J (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 10
DOI: 10.14309/ctg.0000000000000056
INTRODUCTION: Inhibition of tumor growth factor-beta (TGF-beta) receptor type I potentiated the activity of sorafenib in preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor of TGF-beta 1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC treatment.
APA:
Kelley, R.K., Gane, E., Assenat, E., Galle, P.R., Merle, P., Hourmand, I.O.,... Siebler, J. (2019). A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 10. https://doi.org/10.14309/ctg.0000000000000056
MLA:
Kelley, R. K., et al. "A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma." Clinical and Translational Gastroenterology 10 (2019).
BibTeX: Download